Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.
Unit of Infectious Diseases, Hospital Universitario, Instituto de Investigación Sanitaria Hospital, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
J Glob Antimicrob Resist. 2022 Jun;29:215-221. doi: 10.1016/j.jgar.2022.03.014. Epub 2022 Mar 24.
Multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) constitutes an emerging health problem. A predictive score of MDR-PSA infection would allow an early adaptation of empirical antibiotic therapy.
We performed a single-centre case-control (1:2) retrospective study including 100 patients with MDR-PSA and 200 with a non-MDR-PSA infection. Cases and controls were matched by site of infection, clinical characteristics and immunosuppression. A point risk score for prediction of MDR-PSA infection was derived from a logistic regression model. Secondary outcomes (clinical improvement, complications and discharge) were also compared.
Cases with MDR-PSA infection were younger than controls (67.5 vs. 73.0 y; P = 0.031) and have more frequent cirrhosis (9% vs. 2%; P = 0.005). Independent risk factors for MDR-PSA infection were prior antibiotic treatment (80% vs. 50.5%; P < 0.001), prior colonisation with MDR bacteria (41% vs. 13.5%; P < 0.001), hospital-acquired infection (63% vs. 47%; P = 0.009) and septic shock at diagnosis (33% vs. 14%; P < 0.001). Adequate therapy was less frequent in MDR-PSA infections (31% vs. 66.5% for empirical therapy; P < 0.001). The risk score included: previous MDR-PSA isolation (11 points), prior antibiotic use (3 points), hospital-acquired infection (2 points) and septic shock at diagnosis (2 points). It showed an area under the curve of 0.755 (95% CI: 0.70-0.81) and allowed to classify individual risk into various categories: 0-2 points (<20%), 3-5 points (25%-45%), 7-11 points (55%-60%), 13-16 points (75%-87%) and a maximum of 18 points (93%).
Infections due to MDR-PSA have a poorer prognosis than those produced by non-MDR-PSA. Our score could guide empirical therapy for MDR-PSA when P. aeruginosa is isolated.
多重耐药铜绿假单胞菌(MDR-PSA)构成了一个新出现的健康问题。对 MDR-PSA 感染的预测评分将允许早期调整经验性抗生素治疗。
我们进行了一项单中心病例对照(1:2)回顾性研究,纳入了 100 例 MDR-PSA 感染患者和 200 例非 MDR-PSA 感染患者。病例和对照通过感染部位、临床特征和免疫抑制情况进行匹配。从逻辑回归模型中得出预测 MDR-PSA 感染的点风险评分。还比较了次要结局(临床改善、并发症和出院)。
MDR-PSA 感染组的患者比对照组更年轻(67.5 岁 vs. 73.0 岁;P=0.031),且更常患有肝硬化(9% vs. 2%;P=0.005)。MDR-PSA 感染的独立危险因素包括:既往抗生素治疗(80% vs. 50.5%;P<0.001)、既往 MDR 细菌定植(41% vs. 13.5%;P<0.001)、医院获得性感染(63% vs. 47%;P=0.009)和诊断时感染性休克(33% vs. 14%;P<0.001)。MDR-PSA 感染患者的治疗更为充分(经验性治疗的 31% vs. 66.5%;P<0.001)。风险评分包括:既往 MDR-PSA 分离(11 分)、既往抗生素使用(3 分)、医院获得性感染(2 分)和诊断时感染性休克(2 分)。它的曲线下面积为 0.755(95%CI:0.70-0.81),并可以将个体风险分为不同类别:0-2 分(<20%)、3-5 分(25%-45%)、7-11 分(55%-60%)、13-16 分(75%-87%)和最多 18 分(93%)。
MDR-PSA 引起的感染比非 MDR-PSA 引起的感染预后更差。当分离出铜绿假单胞菌时,我们的评分可以指导对 MDR-PSA 的经验性治疗。